Core Insights - Citius Oncology is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), expected in the second half of 2025 [1][2][36] Manufacturing and Supply Chain Readiness - The company has completed commercial-scale manufacturing of LYMPHIR, with sufficient inventory to meet projected demand for 12 to 18 months post-launch [3] - Citius Oncology has secured distribution agreements with top-tier global pharmaceutical logistics partners to ensure broad access and timely delivery across the U.S. [4] KOL Engagement - Engagement with U.S. Key Opinion Leaders (KOLs) and participation in medical congresses have informed the launch strategy and target patient profiles [5][6] - Early interest from the clinical community is evident, with 70 institutional oncology centers signed up via the LYMPHIR website [6] Commercial & Marketing Activities - A targeted launch strategy utilizing a proprietary generative AI model has been developed to enhance interactions with healthcare providers [7] - A comprehensive suite of marketing and educational materials has been created to support the introduction of LYMPHIR [8] Market Access Update - LYMPHIR's inclusion in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and the assignment of a permanent J-code under HCPCS positions the product for efficient reimbursement and coverage at launch [9] Financing and Strategic Partnerships - A recent capital raise by Citius Pharma supports the final preparations for LYMPHIR's commercialization and the planned launch [11] - The company is engaged in strategic partnership discussions to expand LYMPHIR's market reach [11] Product Information - LYMPHIR is a targeted immune therapy indicated for adults with relapsed or refractory CTCL after at least one prior systemic therapy [12][15] - The product was approved by the FDA in August 2024 and is expected to address a market currently exceeding $400 million [36]